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Graves’ Disease is the most common cause of hyperthyroidism. It has multiple 
manifestations and it requires appropriate diagnostic and therapeutic manage-
ment. Once it has been established that the patient is hyperthyroid and the cause is 
GD, the patient and physician must choose between three effective and relatively 
safe initial treatment options: antithyroid drugs (ATDs), radioiodine (RAI) 
therapy, or thyroidectomy. RAI has been used to treat hyperthyroidism for more 
than seven decades. It is well tolerated and complications are rare, except for those 
related to orbitopathy. Most patients are effectively treated with one therapeutic 
dose of I-131. The patient usually notes symptomatic improvement within 3 weeks 
of therapy. However, the full therapeutic effect takes 3 to 6 months because stored 
hormone must first be released. Radioiodine therapy may not initially be effec-
tive in up to 10% of patients. They require repeat treatment, usually with a higher 
administered dose.
Keywords: RAI, hyperthyroidism, therapy, Graves’ disease, Nuclear Medicine, 
theranostics, guidelines
1. Introduction
Thyrotoxicosis is a very common clinical syndrome caused by an excess of 
thyroid hormones in the serum. It results in a generalized acceleration of metabolic 
processes. Occasionally, thyrotoxicosis may be due to other causes. Graves’ disease is 
the commonest cause of hyperthyroidism, typically presenting in patients between 
40–60 years. It is characterized by the presence of thyroid stimulating hormone 
receptor antibodies (TRAbs) but pathogenesis is not completely understood [1]. 
The thyroid stimulating hormone receptor (TSHR) is a transmembrane G-protein-
coupled receptor (GPCR) and when it is activated by thyroid stimulating hormone 
(TSH) it stimulates thyroid hormone production [2]. TRAbs mimic the action of 
TSH leading to hyperthyroidism. Although autoimmune mechanisms are responsi-
ble for the syndrome of GD, management has been largely directed toward control-
ling the hyperthyroidism. Three therapeutic methods are available: (l) antithyroid 
drug therapy (ATD), (2) surgery, and (3) radioiodine treatment (RAI) and have 
proved to be effective, safe and cost-effective. They can be the first-line treatment 
for hyperthyroidism not only due to Graves’ disease, but also due to toxic adenoma, 
and toxic multinodular goiter [3]. Nowadays research has turned its focus on the 
potential use of immunotherapy in GD [4–5]. It is remarkable that the selection of 
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the right therapy for each patient still poses a challenge to the clinician as there is no 
single best therapy for all patients [6].
Radioactive iodine (I-131), has been commonly used for the treatment of 
both benign and malignant thyroid conditions since the 1940s. In the early days 
of nuclear medicine, endocrinologists were attracted to the field by the potential 
of radioiodine for diagnosis and therapy. Today thyroid diagnosis and therapy 
continue to have an important role in the practice of nuclear medicine. The story of 
radioiodine started in 1935 at the Massachusetts Institute of Technology in coop-
eration with the Thyroid Unit of the Massachussetts General Hospital. Diagnostic 
thyroid studies were performed for the first time in 1937 using iodine-128. In 1938, 
not more than one year later, I-130 and I-131 were discovered, followed by the first 
treatment of benign thyroid disease in. Hertz and Roberts were the first to do so on 
March 31, 1941; Hamilton and John Lawrence, began on October 12, 1941. In 1946 
the Oak Ridge National Laboratory produced I-131 for routine use and from this 
time on I-131 treatment is increasingly performed not only in benign thyroid disease 
but also in differential thyroid cancer (DTC) [7].
Nuclear medicine involves the administration of radiopharmaceuticals to 
patients for diagnostic and therapeutic purposes. The theranostic approach is 
an established tool for specific molecular targeting, both for diagnostics and 
therapy. Most radiopharmaceuticals are a combination of radioactive molecule, 
a radionuclide, that permits external detection and a biologically active molecule 
or drug that acts as a carrier and determines localization and biodistribution. For 
a few radiotracers (e.g., radioiodine), the radioactive atoms themselves confer 
the desired localization properties [8]. RAI in GD includes the systemic adminis-
tration of 131-I for selective irradiation of hyperfunctioning thyroid gland. The 
efficacy and safety of this treatment and the advantages over thyroid surgery 
and ATDs have been documented and are widely accepted. Several guidelines, 
protocols and recommendations have been released by various scientific societ-
ies including the European Association of Nuclear Medicine (EANM), and the 
American Society of Nuclear Medicine Molecular Imaging (SNMMI), European 
Thyroid Association (ETA) and American Thyroid Association (ATA) whose 
procedural guidelines are updated in last decade and will be discussed in this 
chapter.
2. Physical and radiobiological properties of (radio)iodine
Physicians responsible for treating thyroid disorders should have an understand-
ing of the clinical pathophysiology and natural history of the disease processes. 
They also should be familiar with iodine uptake and metabolism. Iodine is a 
micronutrient of crucial importance for the health and well-being of all individu-
als. It is mostly obtained from food sources. Thyroid gland plays the central role 
in the metabolism of iodine. When iodine enters the bloodstream it is then taken 
up by thyroid follicular cells through an active transport system the sodium iodide 
symporter (NIS) which is located at the basolateral membrane of the follicular 
cell [9]. Then, peroxidase promotes iodine to bound to thyroglobulin (Tg) and in 
particular to tyrosine which is then iodinated. The latter leads to the formation 
of 3-monoiodotyrosine (MIT) and 3,5-diiodotyrosine (DIT) which are coupled 
afterwards leading to the formation of thyroid hormones. Two molecules of DIT 
form thyroxine (T4) hormone and when one MIT and one DIT molecule couple 
they form Triiodothyronine (T3) hormone. Thyroid hormones remain stored in 
the thyroid cells in a thick fluid that is called colloid. Colloid can store a 3 month 
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supply of thyroid hormones. Thyroid stimulating hormone (TSH) regulates thyroid 
hormone production. In particular it stimulates NIS expression which then activates 
follicular cells through TSH receptor (TSH-R). The uptake and metabolism of the 
radioactive iodine (I-123 and I-131) does not differ from nutritional iodine uptake 
in the normal or hyperfunctional gland.
I-131used for the treatment of thyroid disorders has a physical half life of 
8.4 days and undergoes beta-minus decay emitting a principle primary gamma 
photon of 364 kiloelectron volts (keV) (81% abundance). The 364-keV photons 
are not optimal for gamma cameras. The detection sensitivity for I-131 (i.e. the 
amount of photons detected by the gamma camera) is poor. Approximately half 
of the photons penetrate a 3/8-inch crystal without being detected. Other higher 
energy I-131 emissions will pass though the collimators holes leading to image 
degradation. Beta-minus decay also results to emission of beta particles of 0.606 
megaelectron volt (MeV) (89% abundance) which are responsible for the therapy 
outcome but cannot be used for imaging. The I-131 high-energy beta emissions 
and long physical half-life of gamma emissions result in a high radiation dose to 
the patient, particularly to the thyroid. Thyroid gland which is the target organ 
of RAI treatment receives ultimately a high radiation dose ~0.01Gy/μCi, and this 
defines the maximum applicable administered dose [10]. Radiobiological effects 
of radioiodine on tissues are direct (radiation deposit within DNA) or indirect. 
Indirect effects produce free radicals that in turn react with critical macromol-
ecules. The cellular effect of the ionizing radiation leads to genetic damage, 
mutations, or cell death. The DNA damage from radiation is mediated via a 
combination of direct effects, through breakage of molecular bonds, or indirectly 
through the formation of free radicals. This leads to a decrease in thyroid function 
and/or reduction in thyroid size. There are neither good measures of individual 
radiosensitivity nor ideal methods of predicting the clinical response to RAI 
therapy [11].
3. Treatment choices for graves’ hyperthyroidism
Patients with overt Graves’ hyperthyroidism should be treated with any of the 
following modalities: RAI therapy, ATDs, or thyroidectomy. Once the diagnosis has 
been made, the treating physician and patient should discuss each of the treatment 
options, including the logistics, benefits, expected speed of recovery, drawbacks, 
potential side effects, and costs. This sets the stage for the physician to make 
recommendations based on best clinical judgment and allows the final decision 
to incorporate the personal values and preferences of the patient. The treatment 
selection should also take into account the local availability and the associated costs. 
Whenever surgery is selected as treatment one should consider the use of expert 
high-volume thyroid surgeons with on average lower risk of complications; lack of 
that expertise should be considered against the known risk of alternative choices. 
Long-term continuous treatment of hyperthyroidism with ATDs may be considered 
in selected cases [12]. Despite the use of these three treatments for decades, selec-
tion of the optimal therapy for GD still poses a challenge for both the physician and 
the patient.
3.1 Thyroidectomy
Thyroidectomy, in particular subtotal thyroidectomy, is the oldest way of 
treating hyperthyroidism [13]. A Swiss surgeon, Theodor Kocher (1841–1917) won 
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the Nobel Prize for Medicine and Physiology in 1909 after performing the first 
successful surgeries for GD [14]. Nowadays, thyroidectomy is the least preferable 
therapeutic selection for GD worldwide [15]. However, in some circumstances it 
is regarded as the most preferable treatment option. In particular, it is indicated 
for women who are planning a pregnancy in less than 6 months (provided they 
are rendered euthyroid with ATD), in patients with large goiters (≥80 g) or with 
compressive symptoms, in cases of coexisting hyperparathyroidism which will 
lead to a surgery and when thyroid cancer is suspected. Also, surgery is preferred 
in patients with moderate to severe active Graves orbitopathy (GO), in cases of 
large thyroid nodules that are additionally cold (has lower radiopharmaceutical 
uptake than the surrounding thyroid tissue) on scintigraphy, when TRAb values 
are very high or radioiodine uptake is low. Thyroidectomy should not be consid-
ered in patients with comorbid conditions such as cardiopulmonary disease and 
end-stage malignancy. Lack of access to a high-volume thyroid surgeon may also, 
directs against the choice of surgery. During pregnancy it can be considered as 
an emergency treatment of hyperthyroidism, when rapid control of the latter 
is crucial and ATD therapy cannot be used, but it is followed by a higher rate of 
complications such as hypoparathyroidism and recurrent laryngeal nerve (RLN) 
injury [12].
Thyroidectomy can be associated with postoperative complications, such as 
hypocalcemia, wound infection, hematoma, recurrent laryngeal nerve (RLN) 
injury, and Horner’s syndrome. Those complications are dependent on surgeon’s 
experience and skills as well as on removal approaches and the type and extent 
of the disease, having a great impact on patient’s quality of life. Studies have 
shown that surgeons experience and post surgery complications are inversely 
proportional. In rare cases, after subtotal thyroidectomy recurrence of GD may 
be present [16].
3.2 Antithyroid drugs
ATD represent the predominant therapy in Europe, Asia, and as a bridge 
therapy in the USA [17]. The thionamides, propylthiouracil (PTU), carbimazole 
(CBZ), and the active metabolite of the latter, methimazole (MMI) by inhibiting 
thyroid peroxidase enzymes they cause a decrease in thyroid hormone produc-
tion. Moreover studies have shown that they have an immunosuppressive effect 
resulting in reduction of TSH-RAb levels, intercellular adhesion molecule-1 
(ICAM-1) and soluble IL-2 receptor (sIL-2R) [18]. ATD are indicated especially 
in younger patients and in cases when a short term treatment is needed prior to 
RAI or surgery. Moreover, patients with mild disease (small size of goiter, nega-
tive or low TRAb values), of old age with comorbidities who are at high risk of 
postoperative complications or patients with a history of head and neck irradia-
tion or surgery, are candidates for ATD therapy. In pregnancy ATD are the first 
line therapy for GD. Also ATD are indicated, in cases of people receiving care in 
nursing facilities and therefore radiation safety precautions cannot be preserved, 
in patients with moderate to severe active Graves’ orbitopathy (GO) and in 
those who need more rapid biochemical disease control. Finally, ATD should be 
considered when there is lack of access to an experienced thyroid surgeon [12]. 
Adverse events of antithyroid medication range from milder adverse events such 
ascutaneous eruptions, gastrointestinal disorders and arthralgias to more serious 
complications as agranulocytosis, frank polyarthritis and hepatotoxicity. Adverse 
events of methimazole seem to be dose related (40 mg/day or more) while such 
thing has not been associated pylthiouracil doses [19].
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3.3 RAI therapy
RAI treatment is a very effective therapy of GD. Accordintg to the NICE guidance, 
which is prepared for the National Health Service in England, it is used as first line 
treatment and in cases of hyperthyroidism recurrence post ATD therapy. The aim of 
this therapy is to radiate thyroid cells rendering the patient eu/hypothyroid. Although 
for many years it has been the most preferable treatment in USA, currently there is a 
tendency toward ATD therapy [20]. RAI treatment is performed after failure of ATD 
therapy to control hyperthyroidism or when the latter is contraindicated. Also RAI is 
preferred in patients with commodities who are at high risk of surgical complications, 
or in those with a history of prior surgery or irradiation of the head and neck. RAI 
treatment is the therapy of choice when there is no access to an experienced thyroid 
surgeon and in patients with periodic thyrotoxic hypokalemic paralysis, right heart 
failure pulmonary hypertension, or congestive heart failure [12]. RAI treatment is 
contraindicated when there is suspicion of thyroid cancer, in women who are preg-
nant or are breastfeeding and in those who cannot follow radiation safety rules. As 
RAI treatment has a risk of worsening Graves orbitopathy it is contraindicated in case 
of moderate to severe orbitopathy [12].
4. Patient preparation for RAI therapy
A close collaboration between, endocrinology and nuclear medicine, depart-
ments is required for the management of patients with thyroid disease who are 
candidates for RAI therapy. The determination of the activity, as well as the 
administration of radioiodine are responsibilities of the nuclear medicine physician. 
According to the EANM guidelines for the treatment of benign thyroid disease prior 
to any intervention a detailed medical history is needed including previous thera-
pies for hyperthyroidism and especially any potential intake of iodine-containing 
medication (such as amiodarone and contrast media) or food [21]. The medical 
history should include medical conditions, surgeries, allergies and medications 
(especially those who may interfere with radioiodine uptake). Nuclear medicine 
physician should provide oral and written information about RAI therapy proce-
dure, possible side effects, risk of recurrence and possible retreatment as well as 
radiation safety precautions post RAI therapy [14, 22] and rule out any possibility of 
pregnancy prior treatment. It is mandatory for female patients of childbearing age 
to undergo a pregnancy test 3 days prior to radioiodine administration and provide 
written signed declaration stating that they are not pregnant. Serum pregnancy test 
is preferable than urine test as it is more sensitive [23]. If previous hysterectomy has 
been reported or the patient is in postmenopausal state then the test can be omitted. 
Patients of both sexes should avoid conception 6 months post RAI therapy. RAI 
therapy is contraindicated in breastfeeding and it should be administrated 6 weeks 
to 3 months after lactation is disrupted [21]. To increase radioiodine uptake (RAIU), 
iodine restriction for 1 to 2 weeks and ATD withdrawal 3–7 days before RAI admin-
istration are also recommended.
Serum levels of TSH, FT3, FT4, TPO and TSI should be measured prior RAI 
therapy. Thyroid volume is assessed by ultrasonography (US) and in cases of a large 
goiter magnetic resonance imaging (MRI) is performed in order to estimate possible 
extension in the mediastinum. Computed Tomography (CT) is not preferred as the 
contrast media impair with the radioiodine uptake. Thyroid scintigraphy with 99mTc 
pertechnetate (99mTcO4) and radioiodine is also mandatory to provide metabolic 
information of the organ. Radioactive iodine thyroid uptake (RAIU) at 4-6 h and 
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24 h post administration must be measured. RAIU increases gradually over 24 h but 
in some patients it can be increased rapidly reaching maximum values at 4 to 12 h 
and return to normal after 24 h. In some nuclear medicine departments a fixed dose 
of radioiodine is used, therefore RAIU calculation is not needed.
For nodules >1–1,5 cm, with suspicious findings in US (hypoechoic nodules 
solid or cystic with hypoechoic solid component, with irregular shape, calcifica-
tions and presence of invasion in adjacent structures) which appear in scintigra-
phy as “cold’ or with a decreased uptake, fine needle aspiration (FNA) biopsy is 
recommended [24].
Patients with GD may present with ophthalmopathy. An experienced ophthal-
mologist should estimate the severity of the disease as RAI therapy has been associ-
ated with exacerbation of the ophthalmopathy. Corticosteroid therapy should be 
considered [12]. Studies have shown a possible correlation between Grave’s ophthal-
mopathy (GO) progression post RAI therapy in smokers. Cessation of smoking is 
recommended. RAI therapy in cases of active moderate-to-severe ophthalmopathy 
is contraindicated [25].
As transient elevation of thyroid hormones due to actinic thyroiditis may 
present, ATD therapy should be discontinued approximately one week before 
and be resumed 3–7 days post RAI therapy [18]. B-adrenergic blockade should be 
administered in cases of patients who are at a higher risk of complications due to 
hyperthyroidism.
4.1 Patients’ information for RAI therapy
Patients should be properly and adequately educated concerning the procedures 
they will undergo, the precautions they should take, the outcomes and possible 
adverse events of RAI therapy. Fulfilling these needs requires a collaborative 
approach among patients and health care professionals. Patients should receive 
both written and verbal information. More modern approaches such as mobile 
health (mHealth) could also be helpful [26]. Except for the pre- and posttreat-
ment use of thyroid specific medication, risk of recurrent disease and subsequent 
retreatment(s), early and late side effects, health care professionals should prepare 
the patients regarding radiation protection initiatives to reduce radiation doses to 
family members and general population, according to national rules. Unlike thyroid 
cancer patients, those who receive RAI therapy to treat benign thyroid diseases do 
not need hospitalization.
RAI capsule is administered on an outpatient basis, in authorized Nuclear 
Medicine Departments. After RAI administration the patient is advised to avoid 
eating or drinking anything for 2 h, to allow time for the iodine to be absorbed. 
After this time patients should eat as normal and drink plenty of fluids.
For a few weeks after the treatment patient’s thyroid gland will be radioactive. 
The amount of radioactivity is gradually decreasing. During this period, which 
is estimated for each patient individually, they are advised to avoid or restrict to 
minimum radiation exposure to their environment. Patients are guided to reduce 
the radiation exposure to other people by limiting the amount of time they spend 
with them and by keeping more than three meters away from them. They must not 
share a bed with anyone or sleep within 2 meters of anyone, even if there is a wall 
between beds. For 1–1 ½ months after RAI treatment, patients should not spend 
more than a few minutes each day within arm’s reach of any children or pregnant 
women. Of course, they also need to limit close and prolonged contact with any 
other people, and stay away from crowded places such as cinemas, theaters, public 
transport as well as their work place, where they may be close to the same person for 
a prolonged period of time.
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Although, most of the radioactivity is concentrated in thyroid gland, for a few 
days after RAI treatment, some of the radioiodine is excreted by urine and sweat. 
Around 90% of administered radioiodine activity is excreted mainly through the 
kidneys. Thus, patients with renal insufficiency may retain radioiodine activity 
over a long period, thereby leading to more intense internal exposure to radiation 
than that observed in normal ones [27]. Drinking plenty of fluids and emptying 
bladder frequently can help minimize bladder and adjacent tissues’ exposure. 
Patients are advised to take care with personal hygiene in the first few days after 
treatment. They are instructed to always flush the toilet after use and always wash 
their hands. They are also guided to use their own towels and face cloth. Their 
clothes do not need to be washed separately unless they experience any inconti-
nence [28, 29].
5. Radiation dosimetry and dose calculation
The aim of RAI therapy in GD is to cure hyperthyroidism. This is achieved by 
radiating and therefore destroying thyroid cells. The outcome is the patient to 
return to an euthyroid state or to become hypothyroid. RAI therapy is very effec-
tive, even in cases of possible retreatments, with a cure rate ~ 100%. Individualized 
dose of radioiodine for rendering a patient euthyroid is not feasible [30]. While 
several studies have been conducted, regarding the association between the opti-
mal dose of radioiodine, thyroid’s volume (based on ultrasound) and radioiodine 
turnover [31], there is lack of consensus for the proper dose regimen. The majority 
is in favor of rendering the patient hypothyroid [20] applying high radioiodine 
doses [32] to avoid the possibility of treatment’s failure or relapse of the disease. 
Many nuclear departments apply fixed doses [33]. For rendering a patient euthyroid 
a target dose of ~150 Gy is needed. Higher doses (200–300 Gy) are applied for 
complete ablation.
The following equation recommended by the EANM, is used to estimate the 
appropriate radioiodine dose:












A: radioiodine activity, F: conversion factor (between coulombs per kilogram 
and grays), M: mass of the target volume, D: the target dose.
Radioiodine uptake (RIU) is calculated as follows:
 
Activity in Thyroid Gland
Administered activity
= ´




As it has been mentioned above many nuclear medicine departments apply 
fixed doses, in a range of 200–800 MBq with the commonest applicable doses 
of 400–600 MBq. Estimation of the thyroid size is needed (based on ultra-
sound) [21].
6. RAI therapy outcome
Initially the goal of RAI treatment was to render the patient euthyroid using 
low doses of I-131. Through the years it has become clear that hypothyroidism is an 
inevitable and unpredictable progressive outcome of RAI treatment. Nowadays, 
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hypothyroidism is the desired result of RAI treatment and it has been described by 
many authors as the elimination of hyperthyroidism [34]. RAI treatment fails when 
persistent hyperthyroidism occurs. In the majority of the patients thyroid hor-
mones return to normal levels while clinical symptoms are reduced 4–8 weeks post 
therapy. More than 80% of the patients become hypothyroid 16 weeks post RAI 
therapy. Hypothyroidism, in rare cases can be transient and the patient may return 
to a euthyroid state or remainhyperthyroid. The latter is often associated with no 
decrease of thyroid size [12]. The desired outcome of RAI treatment is dependent 
on multivariable factors such as thyroid size, dose regimens, compensation of 
hyperthyroidism, iodine intake (diet or iodine containing medicine) and the timing 
of the withdrawal of ATDs.
When low dose regimes are preferred, then the possibilities of treatment failure 
increase and ATD continuance and/or RAI retreatment are needed. Unfortunately, 
the field of RAI dose regimen still remains vast and things become more compli-
cated when a fixed dose is compared to an individualized one. Many authors suggest 
that a calculated dose of radioiodine has no advantage over a fixed dose, while oth-
ers recommend individual dose showing correlation between the success of therapy 
and the radiation dose actually absorbed by the thyroid [35]. Other factors that 
influence treatment outcome have been studied as well. In their retrospective cohort 
study, Aung et al. found that RAI treatment failure was more frequent in patients 
with high levels, of thyroid hormone or TRABs and in those who received ATD after 
RAI treatment. There were no correlation found among RAI treatment failure and 
other parameters such as age, sex or smoking. Moreover approximately 7% of the 
patients developed GO and 13.3% of them required surgery. There seemed to be 
a correlation between high thyroid hormone levels and orbitopathy whereas high 
TRAB levels had no effect in the development of orbitopathy [36].
Despite more than 75 years’ experience with RAI treatment of GD, it is not 
always feasible to predict the efficacy of the treatment or the factors that will 
eventually affect it. The “GREAT” score, a predictive model consisting of clini-
cal and biochemical variables has been introduced as a clinical tool that predicts 
the success of antithyroid drug therapy for Graves’ disease. Calculation of the 
GREAT 6-point score is as follows: age (<40 or ≥ 40 years: 1 or 0 point, respec-
tively), goiter (not visible to slightly visible or clearly visible: 0 or 2 points), 
FT4 (<3.1 or ≥ 3.1 ng/dl: 0 or 1 point), and TBII (<6; 6–19.9; >19.9 U/L: 0, 1, or 
2 points) resulting in the GREAT score classes of I (0–1 point), II (2–3 points), 
and III (4–6 points). Higher recurrence rate at the end of follow up is observed 
in GREAT score class III when compared with class II or class I (16.4%) [37]. 
However, GREAT score has been suggested for predicting outcome before the 
start of ATD and to our knowledge there has not been developed yet a clinical 
tool that can estimate RAI results.
7. Follow-up
Regular review of thyroid function tests in patients who have undergone radio-
iodine treatment for thyroid disease is essential to assess the efficacy of the treat-
ment and for timely detection of developing hypothyroidism or post treatment 
immunogenic hyperthyroidism. The first review of thyroid function post RAI 
therapy should be conducted 1–2 months later by assessing TSH, FT4 and total FT3 
values and be repeated every 4–6 weeks for the first 6 months or until the patient 
becomes hypothyroid and is stable on LT4 treatment [13]. In patients at high risk 
for endocrine ophthalmopathy or who have received ATD, follow up is recom-
mended at shorter intervals. In cases of RAI treatment for overt hyperthyroidism, 
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ATD should be initiated 3–5 days post RAI treatment. If RAI retreatment is deemed 
necessary, it can be conducted 6–12 months later. RAI retreatment is not necessary 
in cases of post therapy immunogenic hyperthyroidism; ATD administration for 
a few months is adequate. As it is mentioned above a lifelong testing of thyroid 
function is necessary, even in patients who have returned to an euthyroid state post 
RAI treatment.
8. Adverse events
Actinic thyroiditis is the result of radioiodine therapy. As radioiodine is accumu-
lated by thyroid cells the emitted betta particles cause cellular necrosis and stored 
thyroid hormones are released into the circulation causing a transient exacerbation 
of hyperthyroidism. This effect is greater in radioiodine therapy of a toxic nodular 
goiter as the levels of stored thyroid hormones are bigger [38]. This transient 
elevation of thyroid hormones can be asymptomatic or it can lead to atrial fibril-
lation, heart failure and rarely to thyroid storm with a possible fatal outcome. The 
latter demands admission to an intensive care unit and administration of ATDs and 
steroids (intravenously) as well as b-blockers [16].
Hypothyroidism is another side effect of radioiodine therapy and according to 
the ATA guidelines, it is the main goal of the therapy [12]. This outcome is more 
common in GD rather than in toxic goiter or in solitary hyperfuctionong nodules 
[16]. It requires lifelong follow up and LT4 treatment. In cases of failure to accom-
plish a hypothyroid state post radioiodine treatment, an increase in cardiovascular 
and cerebrovascular deaths has been noted [12].
Actinic thyroiditis is accompanied by thyroid pain and swelling which is preva-
lent the first week post therapy. In a few patients this can lead to dyspnea while the 
majority is asymptomatic. In cases of a large goiter with signs of tracheal compres-
sion, corticosteroids before radioiodine therapy should be considered. Sialadenitis, 
xerostomia or altered taste are adverse effects seen in patients with differentiated 
thyroid cancer who receive radioiodine therapy, however in patients with GD no 
permanent damage has been reported.
Ionizing radiation has been associated with increased incidence of leukemia 
and many solid cancers [39]. An increase in the incidence of thyroid carcinoma 
in children after Chernobyl accident has been reported [40]. Many studies have 
evaluated the possible correlation between radioiodine therapy in GD and the risk 
of malignancy. In a multicenter retrospective cohort study taken place in USA and 
UK, known as Cooperative Thyrotoxicosis Therapy Follow-up Study Group, 35,593 
hyperthyroid patients were included and evaluation of cancer mortality among 
those patients and especially in those who received radioiodine treatment, was 
made. The results showed no significant increase in cancer mortality and this was 
due to the fact that mean doses of radiation among organs except for the thyroid 
were < 200 mGy. It has to be mentioned that the study cannot provide any infor-
mation for the children population as themean age of the patients was 46 years 
[41]. Kitahara et al. [42] extended the previous study and found that radioiodine 
therapy of GD was correlated with a dose dependent increase in the incidence 
of all solid tumors and especially of breast cancer, while Greenspan et al., [43] 
challenged those previous results. Αmeta analysis by Hieu et al., [44] found no 
increase in cancer risk post radioiodine therapy in benign thyroid disorders except 
perhaps for the thyroid, kidney and the stomach cancer, which the authors esti-
mate that it should be investigated with further studies. The latter has also been 
challenged by Salvatori et al., [45] as the main reason for increased incidence of 
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itself. Thyroid hormones through ανβ3, a membrane receptor which is overex-
pressed in tumor cells, play a crucial role in cancer cell proliferation, angiogenesis 
and metastasis.
8. Conclusion
Thyrotoxicosis is a very common clinical syndrome caused by an excess of thyroid 
hormones in the serum. Graves’ disease is the commonest cause of hyperthyroid-
ism. Graves’ disease is the commonest cause of hyperthyroidism. It has multiple 
manifestations and it requires appropriate diagnostic and therapeutic management. 
There are three effective treatment options: RAI therapy, ATDs, or thyroidectomy. 
RAI treatment has been used to treat thyroid disorders, both malignant and benign, 
for many decades and in many cases it is preferred first- line treatment. In Graves’ 
disease radioiodine radiates and therefore destroys the follicle cells of the hyper-
functioning thyroid gland providing a definite therapy of hyperthyroidism as well as 
improving patient’s quality of life. It is well tolerated with rare complications except 
for those related to orbitopathy.
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